Sustained Specific EBOV GP Immunogenicity Five-Years Post-Vaccination: Longitudinal Results from North Kivu and Equateur, Democratic Republic of the Congo

Five years after receiving the rVSV-ZEBOV-GP vaccine during the 2018 Ebola outbreaks in the Democratic Republic of the Congo, a longitudinal study of 1,081 individuals demonstrated that the majority retained sustained detectable anti-EBOV GP antibodies, with response durability varying by prior exposure history and booster administration.

The Gist

The Big Picture: A Five-Year Check-Up

Imagine the Ebola virus as a very dangerous, invisible storm that occasionally hits certain villages in the Democratic Republic of the Congo (DRC). To protect people, scientists introduced a "shield" (the rVSV-ZEBOV-GP vaccine) during outbreaks in 2018.

This study is like a long-term follow-up report. The researchers wanted to know: Five years after putting on that shield, is it still working? They tracked over 1,000 people in two different regions (Beni and Mbandaka) to see if their bodies were still remembering how to fight the virus.

The Main Findings: The Shield Holds Up

The results are encouraging. Five years later, most of the vaccinated people still had "guards" (antibodies) on patrol in their blood.

• The Numbers: About 72% of the people who had no prior exposure to Ebola before getting the vaccine still had detectable antibodies five years later.
• The Analogy: Think of the vaccine as teaching your immune system a specific dance move to fight Ebola. Five years later, most people could still remember the dance, even if they hadn't practiced it recently.

The Two Different Villages (Beni vs. Mbandaka)

The study looked at two different locations, and they behaved slightly differently, like two different classrooms learning the same lesson.

1. Mbandaka (The Experienced Class): In this town, about 29% of people already had some antibodies before they got the shot. It's like a classroom where some students already knew the dance moves.

   • What happened: When these "experienced" students got the vaccine, their bodies reacted strongly. The vaccine acted like a booster shot for their existing memory, making their defense even stronger.
   • The Booster Effect: In Mbandaka, some people got a second dose (a booster) about 4.2 years later. This was like a "refresher course." It gave their antibody levels a massive jump, proving that a second dose works well even years after the first.

2. Beni (The New Class): In this town, almost everyone was new to the dance (only 4% had antibodies before).

   • What happened: The vaccine worked beautifully here too. Because they started from zero, the vaccine taught them the dance from scratch, and they kept remembering it very well for five years.

Who Had the Strongest Shields?

The researchers looked at who kept their antibodies the best:

• Gender: Women tended to keep their antibody levels slightly higher than men. The paper suggests this might be because women often take on more caregiving roles, which could mean more exposure to the virus in the community, acting as a natural "practice session" for their immune systems.
• Age: Older people (50+) showed a slight trend of having lower antibody levels, similar to how an older muscle might not bounce back quite as fast as a younger one.
• Jobs: People with jobs that put them in the forest or around animals (like farmers or hunters) had slightly lower odds of having antibodies compared to healthcare workers. This might be because healthcare workers are constantly reminded of the virus through their work, keeping their immune systems "sharp."

Important Caveats (What the Paper Doesn't Say)

• The "Ceiling" Effect: In Mbandaka, people who already had antibodies before the vaccine didn't get a massive boost in numbers compared to the beginners. It's like trying to fill a glass that is already half-full; you can't add as much water as you can to an empty glass. The vaccine helped, but the "ceiling" of how high the antibodies could go seemed to be reached faster for those who were already exposed.
• Not a Perfect Shield: The paper is careful to say that having these antibodies doesn't guarantee you won't get sick. It's like having a smoke detector; it shows the system is working, but we don't know exactly how loud the alarm needs to be to stop a fire. However, the fact that the antibodies lasted so long is a very good sign.

The Bottom Line

Five years after the emergency vaccine was rolled out in the DRC, the "immune memory" is still strong in most people.

• The vaccine works for a long time.
• A second dose (booster) given years later works very well to wake up the immune system again.
• People who had seen the virus before responded differently than those who hadn't, but both groups benefited.

This study gives us confidence that the vaccine provides long-lasting protection in the real world, not just in a controlled lab setting.

Technical Summary

Technical Summary: Sustained Specific EBOV GP Immunogenicity Five-Years Post-Vaccination

Problem Statement
The Ebola virus disease (EVD) remains a high-consequence pathogen with significant morbidity and mortality, particularly in the Democratic Republic of the Congo (DRC), which has experienced 16 outbreaks since 1976. While the recombinant vesicular stomatitis virus-Zaire Ebolavirus envelope glycoprotein vaccine (rVSV-ZEBOV-GP) has demonstrated high efficacy and safety in clinical trials and emergency ring vaccination campaigns, there is a scarcity of real-world longitudinal data regarding the durability of antibody responses beyond the initial post-vaccination period. Existing studies have primarily focused on short-term immunogenicity or limited cohorts in non-endemic settings, leaving a gap in understanding long-term immune persistence in populations facing recurrent outbreak risks.

Methodology
This study presents a longitudinal cohort analysis of 1,081 individuals vaccinated during the 2018 EVD outbreaks in two geographically distinct provinces of the DRC: Beni (North Kivu, n=599) and Mbandaka (Equateur, n=482). Participants were enrolled under compassionate use protocols for ring vaccination and followed for five years with seven collection periods (baseline, 21 days, 6 months, 1.5 years [Beni only], 2.5 years, 3.5 years, 4.2 years [Mbandaka booster], and 5+ years).

Serologic assessments utilized a pan-filovirus multiplex immunoassay (MIA) targeting EBOV glycoprotein (GP), nucleoprotein (NP), and viral protein 40 (VP40). Reactivity was defined by median fluorescent intensity (MFI) thresholds established against a filovirus-naïve Kinshasa cohort, with seroconversion requiring a four-fold increase over baseline. Statistical analyses employed linear and logistic mixed-effects models to evaluate predictors of antibody titers and seroreactivity over time, stratified by site to account for significant differences in baseline reactivity and booster administration. Covariates included age, sex, education, occupation (categorized by exposure risk), and baseline serostatus.

Key Results

• Sustained Immunogenicity: Five years post-vaccination, 72% of individuals who were naïve at the time of vaccination remained seroreactive to EBOV GP. Overall, 71% of the entire cohort retained detectable antibodies at the five-year mark.
• Site-Specific Variability:
  • Beni: Participants showed a robust and sustained response, with 81% seroreactive at five years. Antibody titers at five years were significantly elevated compared to day-21 levels (β = 0.26, p < 0.001), suggesting potential natural boosting from recurrent outbreaks in the region.
  • Mbandaka: Seroreactivity was lower at five years (57%). However, a subset of participants (n=52) who received a booster dose at 4.2 years demonstrated a significant increase in seroreactivity odds (12.75-fold at 4.2 years and 3.68-fold at 5 years) compared to the initial dose response.
• Predictors of Response:
  • Baseline Reactivity: In Mbandaka, where 28.8% of participants were reactive at baseline, pre-existing reactivity was the strongest independent predictor of post-vaccination seroreactivity (OR = 3.87). This effect was not observed in Beni, where baseline reactivity was only 3.8%.
  • Sex: Male sex was associated with modestly lower antibody titers and odds of seroreactivity compared to females across both sites.
  • Occupation: Occupational groups with zoonotic or community-level exposure (e.g., farmers, hunters) showed trending lower odds of seroreactivity relative to healthcare workers, particularly in Beni.
  • Age: Age was not a statistically significant predictor in multivariate models, though a non-significant trend toward reduced titers in older age groups was observed.
• Booster Efficacy: The administration of a booster dose in Mbandaka resulted in a significant divergence in antibody trajectories, confirming the ability of a delayed second dose to re-elevate antibody levels.

Significance and Claims
The authors claim that this study provides one of the largest and longest real-world evaluations of rVSV-ZEBOV-GP immunogenicity to date. The primary contribution is the demonstration that anti-EBOV GP IgG antibodies can persist for at least five years in a high-risk, endemic setting. The paper posits that while correlates of protection for EVD are not fully established, sustained IgG seroreactivity serves as a critical marker for understanding the durability of immune responses to this pathogen.

The study highlights the variability of immune responses based on geography and prior exposure history, noting that pre-existing immunity (likely from prior exposure to EBOV or related filoviruses) significantly influences post-vaccination outcomes. Furthermore, the data supports the utility of booster doses in maintaining high levels of seroreactivity, particularly in regions experiencing recurrent outbreaks. The authors conclude that these findings reinforce the value of vaccination as a preventative measure and suggest that targeted booster strategies may be warranted for specific demographics, such as older individuals or high-risk occupational groups, given the increasing frequency of EVD outbreaks in the DRC.

Limitations Noted
The paper acknowledges that the multiplex assay provides relative rather than absolute titers and that the single-dilution approach may create an artificial detection ceiling. Additionally, the study notes that seroreactivity does not confirm functional neutralization capacity, and loss to follow-up, while low for the DRC context, remains a potential source of bias. The authors also caution that background reactivity in Mbandaka may stem from exposure to non-pathogenic filoviruses or other related antigens, necessitating further investigation.